Nvp bez235

The HDI romidepsin (Cat #S3020) and the ERK inhibitor ulixertinib (Cat #S7854) were purchased from Selleck Chemicals (Houston, TX, USA). The PI3K inhibitor GDC-0941 (Cat #CT-G0941) and mTOR inhibitors AZD-8055 (Cat #CT-A8055) and NVP-BEZ235 (Cat #CT-BEZ) were from ChemieTek (Indianapolis, IN, USA). The mTOR inhibitor rapamycin (Cat #1292) was obtained from Tocris/R&D Systems (Minneapolis, MN, USA). The BRD inhibitor OTX-015 (Cat #15947) was purchased from Cayman Chemicals (Ann Arbor, MI, USA). The pan-caspase inhibitor Q-VD-OPh (Cat #A1901) was obtained from ApexBio Technology (Houston, TX, USA).

NVP-BEZ235 (BEZ235), NVP-BKM120 (Buparlisib, BKM120), GSK1120212 (Trametinib, JTP-74057), PD0325901, and AZD6244 were purchased from Chemie Tek (Indianapolis, IN). Temozolomide, doxorubicin and paclitaxel were purchased from Sigma. For in vivo studies, BEZ235 and BKM120 were resuspended in NMP (N-methyl-2-pyrrolidone):PEG300 1:9 v:v, and GSK1120212 and PD0325901 were resuspended in 0.5% hydroxypropyl-methylcellulose (Sigma):0.2% Tween 80 (Sigma) (Gilmartin et al., 2011 (link); Kinross et al., 2011 (link)). BKM120, GSK1120212 and PD0325901 were given once daily by oral gavage at 10 ml/kg. Mice were treated with BEZ235 on a 5 days on, 2 days off schedule (Liu et al., 2009 (link)). Vehicle- and drug-treated mice were closely monitored on a daily basis for clinical signs as described above.